Influences on PrEP Uptake and Adherence Among South African Women During Periconception and Pregnancy: A Qualitative Analysis.
HIV prevention
Periconception
PrEP adherence
Pregnancy
Safer conception
South Africa
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
11
06
2022
pubmed:
1
7
2022
medline:
24
1
2023
entrez:
30
6
2022
Statut:
ppublish
Résumé
Pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, yet PrEP delivery to women in periconception and pregnancy has lagged. We report qualitative research from a study evaluating PrEP use as part of safer conception care for 330 South African women. Fifty-two semi-structured interviews were conducted with 25 study participants to identify influences on PrEP adherence. Influences were: (1) changing proximity to male partners; (2) COVID-19 lockdown; (3) mobile lifestyle; (4) PrEP-related stigma; (5) disclosure of PrEP use; and (6) pregnancy and motherhood. Data also revealed important contextual information shaping adherence influences for women, including: (a) not living with partners, (b) partners as drivers of pregnancy intention, and (c) feeling at high risk for HIV. Disclosure of PrEP use, addressing stigma, strategies for traveling with pills, and counseling on prevention effective adherence are promising components of PrEP-inclusive HIV prevention interventions for South African women who are pregnant or planning pregnancy.
Identifiants
pubmed: 35771311
doi: 10.1007/s10461-022-03757-8
pii: 10.1007/s10461-022-03757-8
pmc: PMC9245881
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-217Subventions
Organisme : NIMH NIH HHS
ID : R01 MH108412
Pays : United States
Organisme : NIH HHS
ID : NIMH R01MH108412
Pays : United States
Organisme : NIH HHS
ID : NIMH R01MH108412
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and post-partum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001608.
doi: 10.1371/journal.pmed.1001608
Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and post-partum: a prospective per-coital act analysis among women with HIV-1 infected partners. J Infect Dis. 2018;218(1):16–25.
doi: 10.1093/infdis/jiy113
Johnson LF, Stinson K, Newell ML, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. JAIDS. 2012;59(4):417–25.
Dinh TH, Delaney KP, Goga A, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: a national population-based evaluation. PLoS ONE. 2015;10(5):e0125525.
doi: 10.1371/journal.pone.0125525
Dinh TH, Delaney KP, Goga A, et al. Correction: impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: a national population-based evaluation. PLoS ONE. 2015;10(6):e0130321.
doi: 10.1371/journal.pone.0130321
Matthews LT, Baeten JM, Celum CL, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS. 2010;24(13):1975–82.
doi: 10.1097/QAD.0b013e32833bedeb
Gray RH, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet. 2005;366(9492):1182–8.
doi: 10.1016/S0140-6736(05)67481-8
Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscrodant couples. AIDS. 2011;25(15):1887–95.
doi: 10.1097/QAD.0b013e32834a9338
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach—2nd ed. Geneva, Switzerland, 2016. https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1&isAllowed=y . Accessed 12 Nov 2021.
Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update clinical practice guideline. 2018. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf . Accessed 15 Nov 2021.
Dept. of Health. Republic of South Africa. Guidelines for the provision of pre-exposure prophylaxis (PrEP) to persons at substantial risk of HIV infection. 2020. South%20Africa%20PrEP%20Guidelines_Jan2020.pdf. Accessed 15 Nov 2021.
Dettinger JC, Kinuthia J, Pintye J, et al. PrEP implementation for mothers in antenatal care (PrIMA): study protocol of a cluster randomised trial. BMJ Open. 2019;9: e02512.
doi: 10.1136/bmjopen-2018-025122
Kinuthia J, Dettinger J, Stern J, et al. Risk-based vs. universal PrEP delivery during pregnancy: a cluster randomized trial. Conference on Retroviruses and Opportunistic Infections (CROI). Virtual, 2021 [abstract 707].
Kinuthia J, Pintye J, Abuna F, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38–48.
doi: 10.1016/S2352-3018(19)30335-2
Davey DJ, Mvududu R, Mashele N, Lesosky M, Bekker LG, Gorbach P. High initiation and persistence on pre-exposure prophylaxis (PrEP) in HIV-uninfected pregnant women in Cape Town, South Africa. HIV R4P. Virtual, 2021 [oral abstract #OA07.05LB].
Heffron R, Pintye J, Matthews LT, Weber S, Mugo N. PrEP as peri-conception HIV prevention for women and men. Curr HIV/AIDS Rep. 2016;13(3):131–9.
doi: 10.1007/s11904-016-0312-1
Heffron R, Ngure K, Velloza J, et al. Implementation of a comprehensive safer conception intervention for HIV-serodiscordant couples in Kenya: uptake, use and effectiveness. J Int AIDS Soc. 2019;22(4): e25261.
doi: 10.1002/jia2.25261
Kaida A, Kabakyenga J, Bwana M, et al. High incidence of intended partner pregnancy among men living with HIV in rural Uganda: implications for safer conception services. J Acquir Immune Defic Syndr. 2019;81(5):497–507.
doi: 10.1097/QAI.0000000000002053
van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.
doi: 10.1056/NEJMoa1202614
van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2): e89118.
doi: 10.1371/journal.pone.0089118
van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:F13-19.
doi: 10.1097/QAD.0b013e3283522272
Corneli AL, Deese J, Wang M, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324–31.
doi: 10.1097/QAI.0000000000000158
Corneli A, Perry B, McKenna K, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71(4):452–61.
doi: 10.1097/QAI.0000000000000880
Matthews LT, Jaggernath M, Kriel Y, et al. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa. BMJ Open. 2019;9(7): e027227.
doi: 10.1136/bmjopen-2018-027227
Matthews LT, Jaggernath M, Kriel Y, et al. Oral PrEP use among South African women with plans for pregnancy. Conference on Retroviruses and Opportunistic Infections (CROI). Virtual, 2022 [poster 846].
AARDEX Group. MEMS adherence software. https://www.aardexgroup.com/?gclid=CjwKCAjwzOqKBhAWEiwArQGwaCY7dTnk1uhLF2TuswzCIWy07dcuZaHcsWxUR4tqa8Z2f0NagJuSKRoC-doQAvD_BwE . Accessed 29 Sept 2021.
Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.
doi: 10.1097/QAI.0000000000000172
Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell. 2013;155(3):515–8.
doi: 10.1016/j.cell.2013.09.030
Ware NC, Wyatt MA, Haberer JE, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59(5):463–8.
doi: 10.1097/QAI.0b013e31824a060b
Ware NC, Pisarski EE, Haberer JE, et al. Lay social resources for support of adherence to antiretroviral prophylaxis for HIV prevention among serodiscordant couples in sub-Saharan Africa: a qualitative study. AIDS Behav. 2015;19(5):811–20.
doi: 10.1007/s10461-014-0899-4
Matthews LT, Greener L, Khidir H, et al. “It really proves to us that we are still valuable”: qualitative research to inform a safer conception intervention for men living with HIV in South Africa. PLoS ONE. 2021;16(3):e0240990.
doi: 10.1371/journal.pone.0240990
Averill JB. Matrix analysis as a complementary analytic strategy in qualitative inquiry. Qual Health Res. 2002;12(6):855–66.
doi: 10.1177/104973230201200611
Dzomba A, Tomita A, Govender K, Tanser F. Effects of migration on risky sexual behavior and HIV acquisition in South Africa: a systematic review and meta-analysis, 2000–2017. AIDS Behav. 2019;23(6):1396–430.
doi: 10.1007/s10461-018-2367-z
Gutin SA, Harper GW, Moshashane N, et al. “What if they are pre-conception? What should we do?”: knowledge, practices, and preferences for safer conception among women living with HIV and healthcare providers in Gaborone, Botswana. Front Glob Womens Health. 2020;1: 582463.
doi: 10.3389/fgwh.2020.582463
Reed JB, Shrestha P, Were D, et al. HIV PrEP is more than ART-lite: longitudinal study of real-world PrEP services data identifies missing measures meaningful to HIV prevention programming. J Int AIDS Soc. 2021;24(10): e25827.
doi: 10.1002/jia2.25827
Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29(11):1277–85.
doi: 10.1097/QAD.0000000000000647
Beymer MR, Holloway IW, Pulsipher C, Landovitz RJ. Current and future PrEP medications and modalities: on-demand, injectables, and topicals. Curr HIV/AIDS Rep. 2019;16(4):349–58.
doi: 10.1007/s11904-019-00450-9
Seifert SM, Chen X, Meditz AL, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retrovir. 2016;32(10–11):981–91.
doi: 10.1089/aid.2016.0008
Stranix-Chibanda L, Anderson PL, Kacanek D, et al. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa. Clin Infect Dis. 2021;73(7):e1893–900.
doi: 10.1093/cid/ciaa1872
Crankshaw TL, Matthews LT, Giddy J, et al. A conceptual framework for understanding HIV risk behavior in the context of supporting fertility goals among HIV-serodiscordant couples. Reprod Health Matters. 2012;20(39 Suppl):50–60.
doi: 10.1016/S0968-8080(12)39639-0
Ware NC, Wyatt MA, Pisarski EE, et al. Influences on adherence to antiretroviral therapy (ART) in early-stage HIV disease: qualitative study from Uganda and South Africa. AIDS Behav. 2020;24:2624–36.
doi: 10.1007/s10461-020-02819-z
Davey DLJ, Knight L, Markt-Maloney J, et al. “I had made the decision and no one was going to stop me”—facilitators of PrEP adherence during pregnancy and postpartum in Cape Town, South Africa. AIDS Behav. 2021;25(12):3978–86.
doi: 10.1007/s10461-021-03320-x
Vasquez L, Moll AP, Kacin K, Ndovu NE, Shenoi SV. Perceptions of HIV pre-exposure prophylaxis among young pregnant women from rural KwaZulu-Natal, South Africa. AIDS Patient Care STDs. 2019;33(5):214–9.
doi: 10.1089/apc.2018.0242
Moran A, Mashele N, Mvududu R, et al. Maternal PrEP use in HIV-uninfected pregnant women in South Africa: role of stigma in PrEP initiation, retention and adherence. AIDS Behav. 2022;26(1):205–17.
doi: 10.1007/s10461-021-03374-x
Data from National Institute for Communicable Diseases, South Africa. https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-epidemiological-brief/ . Accessed 21 Mar 2022.